Biopharmaceutical CDMO annual average of ¡è31%
By Lee, Hye-Kyung | translator Kim, Jung-Ju
23.05.11 05:50:52
°¡³ª´Ù¶ó
0
10 billion dollars in 2026
Resolving the risk of outsourcing genes by using an automated system
¡ãKwon Soon-jae, managing director of ENCell, is giving a presentation on the current status of the CDMO market at Bio Korea 2023.
Globally, the CDMO market for biopharmaceuticals is growing at an average annual rate of 31%. If this trend continues, the size of the Cell&Gene Therapy CDMO market is expected to reach 10 billion dollars in 2026. Kwon Soon-jae, managing director of ENCell, announced this at the 'CDMO Partnership for Acceleration of Biopharmaceutical Development session held at the 'Bio Korea 2023' event held on the 10th.Director Kwon explained, "Cell & Gene Therapy is expected to grow 5.5 times in 2026 compared to 2019, and gene therapy is expected to grow 8.7 times." He explained, "If you look at the high CAGR from 2019 to 2026, it will account for 36.3% and 27.6%, respectively." The demand for CMOs and CDMOs has inc
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)